Cargando…

Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers

Targeting the ubiquitin-proteasome system (UPS) - in particular, the proteasome complex - has emerged as an attractive novel cancer therapy. While several proteasome inhibitors have been successfully approved by the Food and Drug Administration for the treatment of hematological malignancies, the cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zagirova, Diana, Autenried, Rebecca, Nelson, Morgan E., Rezvani, Khosrow
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040722/ https://www.ncbi.nlm.nih.gov/pubmed/33854609 http://dx.doi.org/10.7150/jca.52414

Ejemplares similares

Proteasome regulators in pancreatic cancer
por: Murugan, Nirosha J, et al.
Publicado: (2022)

Assessment of murine colorectal cancer by micro-ultrasound using three dimensional reconstruction and non-linear contrast imaging
por: Freeling, Jessica L, et al.
Publicado: (2016)

Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer
por: Morozov, Alexey V., et al.
Publicado: (2019)

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets
por: Beumers, Lukas, et al.
Publicado: (2023)

UBXN2A enhances CHIP‐mediated proteasomal degradation of oncoprotein mortalin‐2 in cancer cells
por: Sane, Sanam, et al.
Publicado: (2018)

UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer
por: Rezvani, Khosrow
Publicado: (2016)

The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
por: Orlowski, Robert Z, et al.
Publicado: (2003)

Heterogeneity of cytotoxic T cell infiltration in breast and colorectal cancer
por: Ziai, James, et al.
Publicado: (2015)

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
por: Raninga, Prahlad V., et al.
Publicado: (2020)

BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death
por: Mañas, Adriana, et al.
Publicado: (2017)

Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
por: Juiz, Natalia Anahi, et al.
Publicado: (2019)

Heterogeneity of CEACAM5 in breast cancer
por: Bechmann, Marc B., et al.
Publicado: (2020)

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
por: Andreani, Cristina, et al.
Publicado: (2017)

Nucleocytoplasmic Translocation of UBXN2A Is Required for Apoptosis during DNA Damage Stresses in Colon Cancer Cells
por: Abdullah, Ammara, et al.
Publicado: (2015)

Proteomic analysis of affinity-purified extracellular proteasomes reveals exclusively 20S complexes
por: Kulichkova, Valentina A., et al.
Publicado: (2017)

Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications
por: Saoudi González, Nadia, et al.
Publicado: (2023)

Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
por: Tsvetkov, Peter, et al.
Publicado: (2015)

Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer
por: Kao, Tzu-Jen, et al.
Publicado: (2021)

Breast cancer heterogeneity: mechanisms, proofs, and implications
por: Hsiao, Yi-Hsuan, et al.
Publicado: (2010)

Uncovering the genomic heterogeneity of multifocal breast cancer
por: Desmedt, Christine, et al.
Publicado: (2015)

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
por: Shi, Yonghua, et al.
Publicado: (2016)

The Ubiquitin Proteasome System in Genome Stability and Cancer
por: Morgan, Jonathan J., et al.
Publicado: (2021)

Relationship between the Ubiquitin–Proteasome System and Autophagy in Colorectal Cancer Tissue
por: Bednarczyk, Martyna, et al.
Publicado: (2023)

Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells
por: Nehybová, Tereza, et al.
Publicado: (2017)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

Visualization of tumor heterogeneity by in situ padlock probe technology in colorectal cancer
por: El-Heliebi, Amin, et al.
Publicado: (2017)

RPGR protein complex regulates proteasome activity and mediates store-operated calcium entry
por: Patnaik, Sarita Rani, et al.
Publicado: (2018)

Proteasome Functioning in Breast Cancer: Connection with Clinical-Pathological Factors
por: Shashova, Elena E., et al.
Publicado: (2014)

Proteasome activity is required for the initiation of precancerous pancreatic lesions
por: Furuyama, Takaki, et al.
Publicado: (2016)

Proteasomal degradation of WT proinsulin in pancreatic beta cells
por: Xu, Xiaoxi, et al.
Publicado: (2022)

Targeting Ubiquitin–Proteasome System With Copper Complexes for Cancer Therapy
por: Chen, Xin, et al.
Publicado: (2021)

Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer
por: Adamo, Patricia, et al.
Publicado: (2017)

Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC
por: Lankes, Katharina, et al.
Publicado: (2020)

A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2
por: Abdullah, Ammara, et al.
Publicado: (2015)

In-gel proteasome assay to determine the activity, amount, and composition of proteasome complexes from mammalian cells or tissues
por: Yazgili, Ayse Seda, et al.
Publicado: (2021)

Colorectal Carcinogenesis, Radiation Quality, and the Ubiquitin-Proteasome Pathway
por: Datta, Kamal, et al.
Publicado: (2016)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
por: Peng, Junjie, et al.
Publicado: (2017)

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells
por: Daniel, Kenyon G, et al.
Publicado: (2005)

Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients
por: Xuan, Do Thi Minh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tr476c8joass2phkgfhkvje4bu